Dose adherence matters with ibrutinib - CLL Support
Dose adherence matters with ibrutinib
You need to be a member of this community to see this post.
Read more about...
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib produces rapid and endurable responses. PFS and DOR not reached at up to 44 months -Steven Coutre's Lymphoma & Myeloma 2015 update
'Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms...
Progression Free Survival (PFS) post Discontinuation of Ibrutinib in E1912 Trial
An update re the E1912 trial reported at iwCLL this year - "patients who stopped ibrutinib for...
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
MUST READ for those on Ibrutinib/Imbruvica - concerning advice in pilot study on lower dosing - incl. danger of starting with a lower dose
I'm repeating in full, this very important advice posted by Dr Rick Furman in the CLL/SLL Groups.io...
del17p CLL? Overall Survival and Progression-Free Survival Are Improved With Ibrutinib
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p...
Related Posts
Comparative analysis of targeted novel therapies (ibrutinib vs. venetoclax) in relapsed, refractory CLL (Feb 2020)- Your opportunity to support affordable access to Ibrutinib and Idelalisib for Aussies - Submissions close next Wed 7th October
- Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies
- Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU
- Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
